Amgen | AMGN - Interest Expense On Debt

Stock Price
338.59
Daily Change
-6.09 -1.77%
Monthly
5.57%
Yearly
17.15%
Q1 Forecast
331.35

Amgen reported $685M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
ALKERMES USD 4.65M 1.35M Dec/2024
Amgen USD 685M 9M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Bristol-Myers Squibb USD 480M 5M Sep/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Exelixis USD 23.4M 3.9M Sep/2023
Genmab DKK 37M 28M Sep/2025
Gilead Sciences USD 254M 6M Jun/2025
GlaxoSmithKline GBP 167M 17M Sep/2025
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Incyte USD 592K 2K Sep/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
J&J USD 18M 290M Sep/2025
Merck USD 327M 22M Sep/2025
Moderna USD 12.14B 12.13B Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025
Novartis USD 281M 8M Sep/2025
Pfizer USD 652M 2M Sep/2025
PTC Therapeutics USD 2.64B 2.61B Sep/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR -25M 252M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Takeda JPY 123.63B 40.49B Dec/2025
Teva Pharmaceutical Industries USD 220M 17M Dec/2025
Ultragenyx Pharmaceutical USD 14.15M 108K Sep/2025
Vertex Pharmaceuticals USD 3.3M 400K Sep/2025